The Centers for Medicare and Medicaid Services (CMS) issued a final decision memo supporting the national coverage determination (NCD) for percutaneous LAAC therapy (NCD 20.34) when specific conditions are met1
This major milestone provides appropriate and uniform coverage for Medicare beneficiaries that is largely consistent with the WATCHMAN FDA label
Our GuidePoint Reimbursement Resources have been updated to reflect the positive NCD to assist physicians and hospitals in seeking coverage and payment consideration of WATCHMAN implants on a case-by-case basis from private payers and provide additional information on the NCD
For questions related to WATCHMAN reimbursement, please call
You are now going to a third‐party website. We don’t review or control and are not responsible for the content on non–Boston Scientific websites.